Evaluating Cryoablation of Metastatic Lung Tumors in Patients—Safety and Efficacy The ECLIPSE Trial—Interim Analysis at 1 Year

Baère, Thierry De; Tsélikas, Lambros; Woodrum, David A.; Abtin, Fereidoun; Littrup, Peter J.; Deschamps, Frédèric; Suh, Robert D.; Aoun, Hussein D.; Callstrom, Matthew R.

doi:10.1097/jto.0000000000000632

Cited by 125 publications

(105 citation statements)

References 34 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After a year at a tumor-specific survival rate of 100 %, new metastases were detected in 40 % of the patients. Although local control could not be achieved in only 5.8 % of patients, the systemic problem of the underlying disease is still present [39]. Numerous retrospective studies confirm this data with there being significant variability regarding local control and survival [40 -42].…”

Section: Lungmentioning

confidence: 48%

Current Technique and Application of Percutaneous Cryotherapy

Mahnken

König

Figiel

2018

Fortschr Röntgenstr

View full text Add to dashboard Cite

ABSTR AC TPurpose Local ablative therapies have become an established treatment option in interventional oncology. Radiofrequency ablation (RFA) and microwave ablation (MWA) are a standard of care in the treatment of hepatocellular carcinoma (HCC). Currently, there is an increasing interest in cryotherapy, one of the oldest ablation techniques. It has some unique characteristics with regard to technology and mechanism of action.Materials and Methods A systematic literature search using the terms cryotherapy, cryosurgery and cryoablation was performed. Selected studies are presented dealing with the mechanism of action, cryobiology and clinical use of percutaneous, image-guided cryoablation. Recent developments and perspectives are presented.Results Cryotherapy is increasingly used and has been included in guidelines for selected tumor entities such as renal cell carcinoma. Cryo-immunotherapy and combination treatments are future areas of interest.Conclusion Cryoabalation may be used in many indications.Its major advantages are its unique visualization and the anesthesiologic effects of cold. While there are only a few prospectively randomized trials, the existing data on the use of cryoablation is promising. Its use appears to be justified in selected tumors, oligometastatic patients and for palliative indications.

show abstract

Section: Lungmentioning

confidence: 48%

Current Technique and Application of Percutaneous Cryotherapy

Mahnken

König

Figiel

2018

Fortschr Röntgenstr

View full text Add to dashboard Cite

show abstract

“…Another study treated 47 non-small cell lung cancer (NSCLC) tumours in 45 patients with a 5-year survival rate of 67.8% ± 15.3%, with results similar to survival benefits seen in RFA [45]. Currently, the only prospective multicentre trial which included sites in both the USA and Europe demonstrated a 1-year local control rate of 94.6% in 60 treated metastatic lung lesions in 40 patients with a mean tumour size of 1.5 cm [46].…”

Section: Clinical Outcomesmentioning

confidence: 93%

Clinical experiences with microwave thermal ablation of lung malignancies

Sidoff

Dupuy

2016

International Journal of Hyperthermia

View full text Add to dashboard Cite

Approximately 30% of early stage lung cancer patients are not surgical candidates due to medical comorbidities, poor cardiopulmonary function and advanced age. These patients are traditionally offered chemotherapy and radiation, which have shown relatively modest improvements in mortality. For over a decade, percutaneous image-guided ablation has emerged as a safe, cost-effective, minimally invasive treatment alternative for patients who would otherwise not qualify for surgery. Although radiofrequency ablation (RFA) is currently the most extensively studied and widely utilised technique in the treatment of lung malignancies, there is a growing body of evidence that microwave ablation (MWA) has several unique benefits over RFA and cryoablation in the lung. This article reviews our institution's clinical experiences in the treatment of lung malignancies with MWA including patient selection, procedural technique, imaging follow-up, treatment outcomes and comparison of ablation techniques. ARTICLE HISTORY

show abstract

“…de Baere and colleagues used the prospective database of 2 French cancer centers' experience of 566 patients treated for primary and secondary pulmonary malignancies with a median overall survival of 62 months. 33 Kaplan-Meier survival estimates at 1, 2, 3, 4, and 5 years were 92.4%, 79.4%, 67.7%, 58.9%, and 51.5%, respectively, thus indicating a survival benefit with such treatment. The only prospective multicenter study enrolled 54 stage IA NSCLC patients with 86.3% and 69.8% overall survival at 1 and 2 years, respectively.…”

Section: Outcomes and Comparisonsmentioning

confidence: 94%

“…It reported a 12-month local tumor control rate of 94.6% with mean tumor size of 1.5 cm. 33 There are few reports in humans regarding the safety and/or efficacy of IRE for the treatment of thoracic malignancies. Theoretical benefits include a narrow transition between the zone of tissue necrosis and healthy tissue, the ability to overcome thermal sinks, and preservation of underlying structure.…”

Section: Outcomes and Comparisonsmentioning

confidence: 99%

Lung Ablation

Xiong

Dupuy²

2016

Journal of Thoracic Imaging

View full text Add to dashboard Cite

Lung cancer had an estimated incidence of 221,200 in 2015, making up 13% of all cancer diagnoses. Tumor ablation is an important treatment option for nonsurgical lung cancer and pulmonary metastatic patients. Radiofrequency ablation has been used for over a decade with newer modalities, microwave ablation, cryoablation, and irreversible electroporation presenting as additional and possibly improved treatment options for patients. This minimally invasive therapy is best for small primary lesions or favorably located metastatic tumors. These technologies can offer palliation and sometimes cure of thoracic malignancies. This article discusses the current available technologies and techniques available for tumor ablation.

show abstract

Evaluating Cryoablation of Metastatic Lung Tumors in Patients—Safety and Efficacy The ECLIPSE Trial—Interim Analysis at 1 Year

Abstract: Cryoablation is a safe and effective treatment for pulmonary metastases with preserved quality of life following intervention.

Cited by 125 publications

References 34 publications

Current Technique and Application of Percutaneous Cryotherapy

Current Technique and Application of Percutaneous Cryotherapy

Clinical experiences with microwave thermal ablation of lung malignancies

Lung Ablation

Contact Info

Product

Resources

About